Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2025-12-26 @ 1:24 AM
Study NCT ID:
NCT06269133
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-27
First Post:
2024-02-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-02-21
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-23
Completion Date Type:
ESTIMATED
First Submit Date:
2024-02-13
First Submit QC Date:
None
Study First Post Date:
2024-02-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-26
Last Update Post Date:
2025-08-27
Last Update Post Date Type:
ESTIMATED